GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theriva Biologics Inc (AMEX:TOVX) » Definitions » Free Cash Flow

TOVX (Theriva Biologics) Free Cash Flow : $-18.84 Mil (TTM As of Sep. 2024)


View and export this data going back to 1993. Start your Free Trial

What is Theriva Biologics Free Cash Flow?

Theriva Biologics's total free cash flow for the months ended in Sep. 2024 was $-3.91 Mil. Its total free cash flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-18.84 Mil.

Theriva Biologics's Free Cash Flow per Share for the months ended in Sep. 2024 was $-3.45. Its free cash flow per share for the trailing twelve months (TTM) ended in Sep. 2024 was $-24.67.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 42.90% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 48.50% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 41.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Free Cash Flow Growth Rate using Free Cash Flow per Share data.

During the past 13 years, Theriva Biologics's highest 3-Year average Free Cash Flow per Share Growth Rate was 66.30% per year. The lowest was -59.00% per year. And the median was 20.40% per year.


Theriva Biologics Free Cash Flow Historical Data

The historical data trend for Theriva Biologics's Free Cash Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theriva Biologics Free Cash Flow Chart

Theriva Biologics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Free Cash Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.87 -12.18 -12.90 -19.20 -19.20

Theriva Biologics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Free Cash Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.08 -6.60 -4.88 -3.45 -3.91

Theriva Biologics Free Cash Flow Calculation

Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company.

Theriva Biologics's Free Cash Flow for the fiscal year that ended in Dec. 2023 is calculated as

Free Cash Flow (A: Dec. 2023 )=Cash Flow from Operations+Capital Expenditure
=-18.996+-0.202
=-19.20

Theriva Biologics's Free Cash Flow for the quarter that ended in Sep. 2024 is calculated as

Free Cash Flow (Q: Sep. 2024 )=Cash Flow from Operations+Capital Expenditure
=-3.913+0
=-3.91

Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.84 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theriva Biologics  (AMEX:TOVX) Free Cash Flow Explanation

Free Cash Flow is very close to Warren Buffett's definition of Owner's Earnings, except that in Warren Buffett's Owner's Earnings, the spending for Property, Plant, and Equipment is only for maintenance (replacement), while in the Free Cash Flow calculation, the cost of new Property, Plant, and Equipment due to business expansion is also deducted. There, Free Cash Flow is more conservative than Owner's Earnings.

In Don Yacktman's calculation of forward rate of return, he uses Free Cash Flow for the calculation. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation.

This is what Yacktman said in his March 2012 interview - when the S&P 500 was at 1400:

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over seven years. The reason we use seven years is because research shows that seven years is the length of the typical business cycle.

Therefore, as of Sep24, Theriva Biologics's Forward Rate of Return (Yacktman) % is

Forward Rate of Return (Yacktman) % (Sep24)=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/1.38+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Free Cash Flow within a report period can be affected by management's decisions of capital spending. Therefore, it is important to look at long term when it comes to Free Cash Flow.


Theriva Biologics Free Cash Flow Related Terms

Thank you for viewing the detailed overview of Theriva Biologics's Free Cash Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Theriva Biologics Business Description

Traded in Other Exchanges
N/A
Address
9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
Executives
Steven A Shallcross director, officer: CEO and CFO C/O ELYS GAME TECHNOLOGY CORP., 130 ADELAIDE STREET WEST, SUITE 701, TORONTO A6 M5H2K4
Francis Tufaro officer: Chief Operating Officer 9605 MEDICAL CENTER DRIVE SUITE 270, ROCKVILLE MD 20850
John J Monahan director
Scott Tarriff director 28 TUDOR ROSE TERRACE, MAHWAH NJ 07430
Randal J Kirk 10 percent owner 1881 GROVE AVENUE, RADFORD VA 24141
Joseph A. Sliman officer: CHIEF MEDICAL OFFICER 9605 MEDICAL CENTER DRIVE, SUITE 270, ROCKVILLE MD 20850
Jeffrey Scott Riley director C/O ADEONA PHARMACEUTICALS, INC, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
Intrexon Corp 10 percent owner 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Charles Evan Ballantyne officer: CHIEF FINANCIAL OFFICER 27 HEARTHSTONE ROAD, HOPKINTON MA 01748
Nelson K. Stacks director C/O ADEONA PHARMACEUTICALS, INC., 3985 RESEARCH PARK DRIVE, SUITE 200, ANN ARBOR MI 48108
Lyon Lyman Max Jr director, officer: CEO & President C/O ADEONA PHARMACEUTICALS, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
David A. Newsome officer: Chief Scientific Officer 3930 VARSITY DRIVE, C/O PIPEX PHARMACEUTICALS, INC., ANN ARBOR MI 48108
James S Kuo director 509 MADISON AVE 14TH FL, NEW YORK NY 10022
Daniel J Dorman director
Wayne George Holman 10 percent owner 430 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022

Theriva Biologics Headlines

From GuruFocus

Q1 2022 Synthetic Biologics Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q3 2022 Theriva Biologics Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q4 2021 Synthetic Biologics Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q3 2023 Theriva Biologics Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q3 2020 Synthetic Biologics Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q3 2019 Synthetic Biologics Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q1 2019 Synthetic Biologics Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q2 2022 Synthetic Biologics Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Synthetic Biologics Inc Operational Update Call Transcript

By GuruFocus Research 02-15-2024